ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02148796
Recruitment Status : Recruiting
First Posted : May 28, 2014
Last Update Posted : January 20, 2017
Sponsor:
Information provided by (Responsible Party):
University of Arizona

Brief Summary:
The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a third observation year after therapy

Condition or disease Intervention/treatment Phase
Asthma Wheezing Drug: Broncho-Vaxom Other: Placebo Phase 2

Detailed Description:
This is a 36 month parallel arm, double-blind, placebo-controlled trial for the prevention of WLRI into the third to fifth year of life (30 to 54 mo inclusive) in young children (6-18 months old) at increased risk for asthma. The trial will be divided into 2 periods. During the initial treatment period (first and second years in the study) participants will receive Broncho-Vaxom® (3.5 mg) or placebo for ten days each month for two consecutive years. This period will allow the observation of key secondary outcomes while participants are receiving therapy. A rolling enrollment strategy will be used anticipating a two year enrollment period for the whole study. The second period (third year in the study) will be a one year observation of the time to occurrence of the first WLRI episode (primary outcome) while off study drug along with the secondary outcomes noted above. During both the treatment and observation periods, participants will be managed by study physicians using a rescue algorithm applied in the PEAK (Prevention of Early Asthma in Kids) trial commensurate with the NAEPP-EPR (National Asthma Education and Prevention Program - Expert Panel Report) III guidelines.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1076 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)
Actual Study Start Date : January 3, 2017
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : April 30, 2022

Arm Intervention/treatment
Active Comparator: Broncho-Vaxom
One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
Drug: Broncho-Vaxom
Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma SA, Switzerland; Storage: Store in the original package
Other Names:
  • OM-85 BV VEGETAL
  • Broncho-Vaxom concentrate (bacterial lysate)

Placebo Comparator: Placebo
A placebo capsule will be used that will be indistinguishable from the active study drug.
Other: Placebo
A placebo capsule will be used that will be indistinguishable from the active study drug.




Primary Outcome Measures :
  1. The time to the occurrence of the first WLRI episode in the third observation year while not receiving study drug [ Time Frame: 25 to 36 months +/- 1 month ]

Secondary Outcome Measures :
  1. The time to first WLRI during the two treatment years while receiving study drug [ Time Frame: 0 to 24 months +/- 1 month ]
  2. The annualized rate of WLRI episodes during the two years while receiving study drug [ Time Frame: 0 to 24 months +/- 1 month ]
  3. The annualized rate of WLRI episodes during the third observation year while not receiving study drug [ Time Frame: 25 to 36 months +/- 1 month ]
  4. The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the two treatment years while receiving study drug. [ Time Frame: 0 to 24 months +/- 1 month ]

    SWLRI episodes are defined as cough and wheezing > 24 hours AND any one of the following:

    • Use of more than 6 albuterol treatments in ≤48 hours.
    • Unscheduled care visit for acute wheezing in doctor's office, urgent care or emergency department -or- hospitalization for wheezing.
    • Use of systemic corticosteroid prescribed by a licensed medical provider for a wheezing illness with or without a clinical visit.
    • The annualized rate of SWLRI episodes during the two years while receiving study drug.

  5. The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the third observation year while not receiving study drug. [ Time Frame: 25 to 36 months +/- 1 month ]
  6. Number of participants with adverse events [ Time Frame: 0 to 24 months +/- 1 month ]
    Safety and tolerability of Broncho-Vaxom® while receiving study drug during the two year treatment period

  7. Number of participants with adverse events [ Time Frame: 25 to 36 months +/- 1 month ]
    Safety and tolerability of Broncho-Vaxom® while receiving study drug during the two year treatment period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 18 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adequate completion of informed consent process with written documentation. The participant's legally acceptable representative must have provided the appropriate written informed consent. Assent forms will not be used due to the age of the participant population; however, for procedures later in the study when participants are older, age appropriate assent will be obtained, if required by local IRB.
  • Age: 6-18 months of age inclusive at randomization which means 5 to 17 months of age inclusive on entry into the one month run-in period. At least half of all enrolled children will be between 6 and 12 months of age at randomization.
  • Participants will meet at least one of the following criteria, which have been associated with an increased risk of wheezing respiratory illnesses and asthma: a) Parental history of asthma -or- b) Physician-diagnosed atopic dermatitis in the participant.
  • Participants may be either male or female.
  • Participants will have at least one parent/guardian who can communicate with the study staff to allow assessment of study outcomes. All study materials used by parent/guardian will be made available in English and in Spanish.

The child's parent/guardian must have a working direct contact telephone.

Exclusion Criteria:

  • Participants may not have had more than two prior WLRI episodes.
  • Participants may not have had any SWLRI episodes.
  • Participants may not have a physician's diagnosis of asthma.
  • Participants may not have a systemic illness (other than allergy) including (but not limited to) recurrent seizures, chronic gastroesophageal reflux (GER) requiring medical treatment, major congenital anomalies, physical and intellectual delay, cerebral palsy, chest surgery, tuberculosis or other chronic infections, primary or secondary immunodeficiency, gastrointestinal malformation or disease or cardiac disorder (except a hemodynamically insignificant ASD, VSD or benign heart murmur).
  • Participants may not have been born earlier than 36 weeks of gestation.
  • Participants may not have received oxygen for more than 5 days in the neonatal period, or received mechanical ventilation with the exclusion of ventilation during anesthesia for a minor surgical procedure.
  • Participants may not have significant neurodevelopmental delay.
  • Participants may not be below the 3rd percentile for weight.
  • Participants may not have any other chronic lung disease; e.g. chronic lung disease of prematurity (CLDP) or cystic fibrosis.
  • Participants may not have a history of any life-threatening respiratory illness that required intubation and mechanical ventilation.
  • The participant's family may not be expected to relocate out of study area within 3 years of the initiation of the study.
  • Participants may not have received inhaled or systemic corticosteroids for respiratory related illness ever, or for other conditions in the month prior to randomization.
  • Participants may not have ever received immunotherapy.
  • Participants may not have ever received i.v. gammaglobulins or systemic immunosuppressants.
  • Participants may not have received probiotics (Lactobacilli and Bifidobacteria) in medicinal form; (i.e. not including food), regularly for more than 4 months in the 6 to <12 mo age group or 6 months in the 12 to 18 month group prior to enrollment.
  • Participant has known sensitivity to any of the study products and any of the ingredients to be administered.
  • Participant has previously been randomized in this study. Participants who failed run-in and were not randomized may have study participation terminated and then be re-enrolled for a second run-in period.
  • Participant is currently enrolled in or has completed any other investigational device or drug study <30 days prior to screening, or is receiving other investigational agent(s).
  • Participant has a significant medical condition(s), anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the participant, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures, in the Investigator's opinion.
  • The one month run-in period will be used to evaluate adherence to study drug administration and electronic communication. At randomization the participant must continue to meet enrolment criteria and also have demonstrated 80% adherence to the placebo during treatment period; i.e. 8 out of 10 days and a75% response rate to weekly mobile phone text queries; i.e. 3 out of 4 weekly text queries.
  • Ongoing infection (of any organ system) at the time of randomization. This includes infections that are being adequately treated.
  • Unable or unlikely to complete study assessments or the study intervention poses undue risk to patient in the opinion of the Investigator.
  • Families will speak English and/or Spanish.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02148796


Contacts
Contact: Fernando D Martinez, MD 520-626-5954 fdmartin@email.arizona.edu
Contact: Liz Firmage 520-626-4272 beckette@email.arizona.edu

Locations
United States, Arizona
University of Arizona Recruiting
Tucson, Arizona, United States, 85724
Contact: Wayne J Morgan, MD    520-626-6754    wmorgan@arc.ARIZONA.EDU   
Principal Investigator: Wayne J Morgan, MD         
United States, District of Columbia
Children's National Health System Recruiting
Washington, District of Columbia, United States, 20037
Contact: Stephen Teach, MD    202-476-6215      
Principal Investigator: Stephen Teach, MD         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Anne Fitzpatrick, PhD    404-727-9112    amentro@emory.edu   
Principal Investigator: Anne Fitzpatrick, PhD         
United States, Massachusetts
Boston Children's Hospital, Harvard University Recruiting
Boston, Massachusetts, United States, 02115
Contact: Wanda Phipatanakul, MD    617-355-6117    wanda.phipatanakul@childrens.harvard.edu   
Principal Investigator: Wanda Phipatanakul, MD         
United States, Missouri
Washington University Recruiting
St. Louis, Missouri, United States, 63110
Contact: Leonard Bacharier, MD    314-454-2284      
Principal Investigator: Leonard Bacharier, MD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Meyer Kattan, MD    212-305-5122    mk2833@columbia.edu   
Principal Investigator: Meyer Kattan, MD         
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792-4108
Contact: Dan J Jackson, MD    608-263-7686    djj@medicine.wisc.edu   
Principal Investigator: Dan J Jackson, MD         
Sponsors and Collaborators
University of Arizona
Investigators
Principal Investigator: Fernando D Martinez, MD University of Arizona
Study Director: Wayne J Morgan, MD University of Arizona
Study Director: Dave T Mauger, PhD Penn State University, Data Coordinating Center

Publications:
Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, Haahtela T, Lambrecht BN, Postma DS, Sunyer J, Valenta R, Akdis CA, Annesi-Maesano I, Arno A, Bachert C, Ballester F, Basagana X, Baumgartner U, Bindslev-Jensen C, Brunekreef B, Carlsen KH, Chatzi L, Crameri R, Eveno E, Forastiere F, Garcia-Aymerich J, Guerra S, Hammad H, Heinrich J, Hirsch D, Jacquemin B, Kauffmann F, Kerkhof M, Kogevinas M, Koppelman GH, Kowalski ML, Lau S, Lodrup-Carlsen KC, Lopez-Botet M, Lotvall J, Lupinek C, Maier D, Makela MJ, Martinez FD, Mestres J, Momas I, Nawijn MC, Neubauer A, Oddie S, Palkonen S, Pin I, Pison C, Rancé F, Reitamo S, Rial-Sebbag E, Salapatas M, Siroux V, Smagghe D, Torrent M, Toskala E, van Cauwenberge P, van Oosterhout AJ, Varraso R, von Hertzen L, Wickman M, Wijmenga C, Worm M, Wright J, Zuberbier T. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy. 2011 May;66(5):596-604. doi: 10.1111/j.1398-9995.2010.02534.x. Epub 2011 Jan 24. Review.
De Prost Y - Clinical Study Report (BV-2002/1) Multicentric, randomized, double-blind, placebo-controlled study of the efficacy and safety of Broncho-Vaxom® (OM-85 BV) in children suffering from atopic dermatitis. - Clinical Study Report (30 January 2008).
FDA Center for Drug Evaluation and Research (CDER) - Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children. Guidance for Industry: March 2007.
NHIS (2011)] National Health Interview Survey Data - Current Asthma Population Estimates. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention Hyattsville, MD: http://www.cdc.gov/asthma/nhis/2011/data.htm
NHLBI. National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma; NIH Publication Number 08-5846. October 2007.
Principi N - Clinical Study Report (BV-2005/01) Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom in Children Suffering from Recurrent Upper Respiratory Tract Infections. - Clinical Study Report (2 October 2012a).
Principi N - Clinical Study Report (EBV09/01) Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom® Drops in Children Suffering from Recurrent Respiratory Tract Infections. - Clinical Study Report (23 October 2012b).
Spertini F - Clinical Study Report (BV-2007/03) Efficacy of Broncho-Vaxom® in Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study. - Clinical Study Report (31 July 2009)

Responsible Party: University of Arizona
ClinicalTrials.gov Identifier: NCT02148796     History of Changes
Other Study ID Numbers: ORBEX-BV2014/06
First Posted: May 28, 2014    Key Record Dates
Last Update Posted: January 20, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University of Arizona:
Wheezing
Lower respiratory tract illness
Asthma
Atopy

Additional relevant MeSH terms:
Respiratory Sounds
Signs and Symptoms, Respiratory
Signs and Symptoms
Broncho-Vaxom
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs